Drugs / GS1168 injection
GS1168 injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07318909 | Dec 2025 → Aug 2027 expected | phenylketonuria | Gritgen Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS1168 injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318909 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-Associated Virus Vector Expressing Human Phenylalanine Hydroxylase Gene” NCT07318909 ↗ |
| Route | Intravenous | “single intravenous administration of GS1168 injection” NCT07318909 ↗ |